Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism

Clinica Chimica Acta

Volumn 254, Issue 1, 1996, Pages 85-92

  Lang, James E ^a   Wang, Ping ^a   Glueck, C J ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; LEVOTHYROXINE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; THYROXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; MALE; MYOPATHY; PRIORITY JOURNAL; CASE REPORT; MIDDLE AGED; NEUROMUSCULAR DISEASE;

AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; FATTY ACIDS, MONOUNSATURATED; FEMALE; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; HYPOTHYROIDISM; INDOLES; LOVASTATIN; MALE; MIDDLE AGED; NEUROMUSCULAR DISEASES; SIMVASTATIN; THYROXINE;

EID: 0030588045     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-8981(96)06376-0     Document Type: Article

References (14)

1. [1] AACE Clinical Practice Guidelines for the evaluation and treatment of hyperthyroidism and hypothyroidism. American College of Endocrinology Syn-57B, 1995.
2. [2] Mason RL, Hunt HM, Hurxthal E. Blood cholesterol values in hyperthyroidism and hypothyroidism: their significance. New Engl J Med 1930;203:1273-1278.
3. [3] Olukoga AO, Crowley VEF, Lawal A, Weinkove C. Hyperlipidaemia and hypothyroidism. Br Med J 1994;308:918.
4. [4] Caron P, Calazel C, Parra NJ, Hoff M, Lovuet JP. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. Clin Endocrinol 1990;33:519-523.
5. [5] Dickman T, Lansberg PJ, Kastelein JJP, Wiersinga WM. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 1995;155:1490-1495.
6. [6] Glueck CJ, Lang JE, Tracy T, Speirs J. The common finding of covert hypothyroidism at initial clinical evaluation for hyperlipoproteinemia. Clin Chim Acta 1991;201:113-122.
7. [7] O'Kane MJ, Neely RDG, Trimble ERT, Nicolls DLP. The incidence of hypothyroidism in new referrals to a hospital lipid clinic. Ann Clin Biochem 1991;28:509-511.
8. [8] Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). J Am Med Assoc 1993;269:3015-3023.
9. [9] Al-Jubouri MKA, Briston PG, Sinclair D, Chinn RH, Young RM. Myxoedema revealed by simvastatin induced myopathy. Br Med J 1994;308:588.
10. [10] Harle JR, Toussirot E, Disdier P, Drancourt M, Weiller PJ. L'hypothyroidie potentialise-telle la toxicite musculaire des fibrates. Rev Med Intern 1990;11:336.
11. [11] Glueck CJ, Lang JE. Lipoprotein metabolism in the elderly. In: Abrams WB, Beers MH, Berkow RB, eds. The Merck manual of geriatrics. Rahway, NJ: Merck, 1995;1023-1052.
12. [12] Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart Lung and Blood Institute Lipid Standardization program. An approach to accurate and precise lipid measures. Clin Lab Med 1989;9:105-135.
13. [13] Glueck CJ, Lang JE, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994;123:59-64.
14. [14] Bradford RH, Shear CL, Chremos AN et al. Expanded clinical evaluation of Lovastatin (EXCEL) study results: two year efficacy and safety follow-up. Am J Cardiol 1994;74:667-673.